{"id":1022584,"date":"2026-11-19T08:19:12","date_gmt":"2026-11-19T13:19:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\/"},"modified":"2026-11-19T08:19:12","modified_gmt":"2026-11-19T13:19:12","slug":"altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\/","title":{"rendered":"Altimmune to Participate in the 9th Annual Evercore Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MORRISTOWN, N.J., Nov.  19, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=F631HSaBO3HhutOCR2hohAGCDr7nAMXHhPu562qNk923N5MPCjgPZzB5XZFEkAYKJoRUvhLML8wxEBvGfWQQ5bM0iuJwcC57gGS0HRJZWH8LGB56HjK4S8ybT_VCmnJcXhgHXLtkQZwCmfaZ9d21RaBdcKQdJ2yKC_sZRngKiS_ZOtzLtfrirD_ooVMhkCf4R3lx940HhvAeqV6qgmHI047MGriB_Gr18I7E4tY9Z8c=\" rel=\"nofollow\" target=\"_blank\">Altimmune, Inc.<\/a> (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon\/GLP-1 dual receptor agonist, in serious liver diseases, today announced that management will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026, at 3:25 p.m. ET.<\/p>\n<p align=\"justify\">A webcast of the fireside chat will be available via the\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LwkfpKQ3kV416fEOxjAGy-VJeRGAJlcPbPTmB2TlJPypAo-C6-2QHSI9fs18MvYw5Cap0zGafEZYRCfqPls20atR7P3UJQQpw52Qa91ZSIjBhk-mexHxSdKlJtBtyF3f3LeKoYgIqPpn1a-ANE7AbKh-LAJh_UO0c_Lj2cyo6pc25YjGNKRCCquTMSVN0HVqGqyLysMvwypP1fpEXiSdCNhWv5TLtml98S-WM3ocj1sBj10jt2nKiudCMYMeDTK84ioqnZyspYG3NkwmIPP81g==\" rel=\"nofollow\" target=\"_blank\">Events<\/a>\u00a0section of the Altimmune website.<\/p>\n<p align=\"justify\">\n        <strong>About Altimmune <\/strong><br \/>\n        <br \/>Altimmune is a biopharmaceutical company developing pemvidutide for patients with serious liver diseases. Pemvidutide, a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio, is in late-stage clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), recently showed robust results in the RECLAIM Phase 2 trial in alcohol use disorder (AUD) and is being studied in alcohol-associated liver disease (ALD).For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LyG_IDI2App9ETgplQNEtQGAfmgOwclRJDwLxCIMdeD48ajNjhbut9ig04I2ctcSeRfqRYiapcdyZ05z7EbR76K5ih0qkquXbSIS1B0Sz3sCa1FR34IlGvZD9U4ht_uV0wrmAJVX6IKeFO2IfCWjwpsrXFBUdxQtev1dUzcCo1cKGj51KWfEYFXv19Uj3edy6QsESnlndHdVw-CadYJGUmAGCzyrUcVmMWoWVqSJ6SnJnFWzoQlIiE3Ri-2mtuKviZ5sUxw8V72IfJoRRvd05c8qqU3xtrc1LZThEdM_vG2kbOfw5luIDbHw4X-IR3dr-PNbHalvKCYfUJKCbjJiNTHMXjyMpzf40bh2aktKmME16sJL7uFFoqIFx4ufo8INj2U01kE6lt98gL5mO2ev7Qfc0eRNXW8yhW_QIB7Yb2bO_Ep3HfbpKI0p1exlLf8ro7UNw9dtuXrlsyOMCe6pyaPaD8F7mcqjx2duQ8FWfqE=\" rel=\"nofollow\" target=\"_blank\">www.altimmune.com<\/a>.<\/p>\n<p align=\"justify\">Follow @Altimmune, Inc. on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YL2EYkms6xp8yIOn29tdslU249gPEAS2pHfOqko5LLjx7wVRGBZV9C-BP70s9SFQaLKNmotd1yQetku4JJXHO9qoMpWnF4n9mw_ByZo_4ms=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a><br \/>Follow @AltimmuneInc on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wf2rpRjLGCF6oExDFiBwvMncP3N0BvxvJyHt2iYow1ZkFdBwI4HvioWvhw749zyLz2FjtIdePyz5hf47pX-1ew==\" rel=\"nofollow\" target=\"_blank\">X<\/a><\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Luis Sanay, CFA<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4Mw-l_iXVnALoE-FoSW1Hpx9Cu6eX_IZLLZ3Dq4SoYmL-Oad8bJjA4OAph2bhgg3RfCnaJe6qp4rsHvpDJcDx11JcDHYTIlGzUK8B3mam_k=\" rel=\"nofollow\" target=\"_blank\">ir@altimmune.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Marisa Sharkey<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hWoERzApYLsgYmVymua9AbJGhcVYE3es3DChPmRI4vThp1VwRqvNABW_CfwVEm2T-c3dQ6sKk3Sed0KiK2srKyE3Gqy_5OeK7PW7TjT5y6g=\" rel=\"nofollow\" target=\"_blank\">media@altimmune.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MDkwMCM3OTc1MDEyIzIwMTA2NzY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODBlNzZjZGMtOTg5ZC00MzhmLWFhOTctOWRiZTY3ZTdlNDY0LTEwMjIyNDktMjAyNi0xMS0xOS1lbg==\/tiny\/Altimmune-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MORRISTOWN, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon\/GLP-1 dual receptor agonist, in serious liver diseases, today announced that management will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026, at 3:25 p.m. ET. A webcast of the fireside chat will be available via the\u00a0Events\u00a0section of the Altimmune website. About Altimmune Altimmune is a biopharmaceutical company developing pemvidutide for patients with serious liver diseases. Pemvidutide, a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio, is in late-stage clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), recently showed robust results in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Altimmune to Participate in the 9th Annual Evercore Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1022584","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Altimmune to Participate in the 9th Annual Evercore Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Altimmune to Participate in the 9th Annual Evercore Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MORRISTOWN, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon\/GLP-1 dual receptor agonist, in serious liver diseases, today announced that management will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026, at 3:25 p.m. ET. A webcast of the fireside chat will be available via the\u00a0Events\u00a0section of the Altimmune website. About Altimmune Altimmune is a biopharmaceutical company developing pemvidutide for patients with serious liver diseases. Pemvidutide, a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio, is in late-stage clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), recently showed robust results in &hellip; Continue reading &quot;Altimmune to Participate in the 9th Annual Evercore Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-19T13:19:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MDkwMCM3OTc1MDEyIzIwMTA2NzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Altimmune to Participate in the 9th Annual Evercore Healthcare Conference\",\"datePublished\":\"2026-11-19T13:19:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\\\/\"},\"wordCount\":178,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg4MDkwMCM3OTc1MDEyIzIwMTA2NzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\\\/\",\"name\":\"Altimmune to Participate in the 9th Annual Evercore Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg4MDkwMCM3OTc1MDEyIzIwMTA2NzY=\",\"datePublished\":\"2026-11-19T13:19:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg4MDkwMCM3OTc1MDEyIzIwMTA2NzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg4MDkwMCM3OTc1MDEyIzIwMTA2NzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Altimmune to Participate in the 9th Annual Evercore Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Altimmune to Participate in the 9th Annual Evercore Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Altimmune to Participate in the 9th Annual Evercore Healthcare Conference - Market Newsdesk","og_description":"MORRISTOWN, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon\/GLP-1 dual receptor agonist, in serious liver diseases, today announced that management will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026, at 3:25 p.m. ET. A webcast of the fireside chat will be available via the\u00a0Events\u00a0section of the Altimmune website. About Altimmune Altimmune is a biopharmaceutical company developing pemvidutide for patients with serious liver diseases. Pemvidutide, a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio, is in late-stage clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), recently showed robust results in &hellip; Continue reading \"Altimmune to Participate in the 9th Annual Evercore Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-19T13:19:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MDkwMCM3OTc1MDEyIzIwMTA2NzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Altimmune to Participate in the 9th Annual Evercore Healthcare Conference","datePublished":"2026-11-19T13:19:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\/"},"wordCount":178,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MDkwMCM3OTc1MDEyIzIwMTA2NzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\/","name":"Altimmune to Participate in the 9th Annual Evercore Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MDkwMCM3OTc1MDEyIzIwMTA2NzY=","datePublished":"2026-11-19T13:19:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MDkwMCM3OTc1MDEyIzIwMTA2NzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MDkwMCM3OTc1MDEyIzIwMTA2NzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-9th-annual-evercore-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Altimmune to Participate in the 9th Annual Evercore Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1022584","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1022584"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1022584\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1022584"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1022584"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1022584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}